

Announcement Summary

---

**Entity name**

PARADIGM BIOPHARMACEUTICALS LIMITED..

**Announcement Type**

New announcement

**Date of this announcement**

Thursday October 08, 2026

**Details of +securities that have ceased**

| ASX +security code | Security description | Number of +securities that have ceased | The +securities have ceased due to                                       | Date of cessation |
|--------------------|----------------------|----------------------------------------|--------------------------------------------------------------------------|-------------------|
| PAAAD              | CONVERTIBLE NOTES    | 1,171,477                              | Repayment or redemption of +convertible debt security without conversion | 08/10/2026        |

Refer to next page for full details of the announcement

Part 1 - Announcement Details

---

**1.1 Name of +Entity**

PARADIGM BIOPHARMACEUTICALS LIMITED..

We (the entity named above) provide the following information about our issued capital.

**1.2 Registered Number Type**

ACN

**Registration Number**

169346963

**1.3 ASX issuer code**

PAR

**1.4 The announcement is**

New announcement

**1.5 Date of this announcement**

8/10/2026

Part 2 - Details of +equity securities or +debt securities that have ceased

---

**ASX +Security Code and Description**

PARAAD : CONVERTIBLE NOTES

**Unquoted +equity securities that have ceased**

**Number of securities that have ceased**

1,171,477

**Reason for cessation**

Repayment or redemption of +convertible debt security without conversion

**Date of cessation**

8/10/2026

**Is the entity paying any consideration for the cessation?**

Yes

**In what currency is the consideration being paid?** **Consideration amount per +security paid by the entity for the cessation**

USD - US Dollar

USD 1.198900000000

**Any other information the entity wishes to notify to ASX about the cessation?**

Part 3 - Issued capital following changes

**Following the cessation of the +securities the subject of this notification, the issued capital of the entity will comprise:**

The figures in parts 3.1 and 3.2 below are automatically generated and may not reflect the entity's current issued capital if other Appendix 2A, Appendix 3G or Appendix 3H forms are currently with ASX for processing.

**3.1 Quoted +equity securities and +debt securities (total number of each +class of +securities quoted on ASX)**

| <b>ASX +security code and description</b> | <b>Total number of +securities on issue</b> |
|-------------------------------------------|---------------------------------------------|
| PAR : ORDINARY FULLY PAID                 | 626,433,356                                 |
| PAROB : OPTION EXPIRING 01-DEC-2026       | 116,360,866                                 |

**3.2 Unquoted +equity securities (total number of each +class of +equity securities issued but not quoted on ASX)**

| <b>ASX +security code and description</b>      | <b>Total number of +securities on issue</b> |
|------------------------------------------------|---------------------------------------------|
| PARAAC : PERFORMANCE RIGHTS                    | 11,127,100                                  |
| PARAR : OPTION EXPIRING 11-FEB-2028 EX \$1.00  | 151,293                                     |
| PARAAE : OPTION EXPIRING 30-JUN-2027 EX \$0.65 | 3,000,000                                   |
| PARAAD : CONVERTIBLE NOTES                     | 3,125,708                                   |

Note: the figures stated in the tables above are used to calculate the total market capitalisation of the entity published by ASX from time to time. The table will not include those classes of +securities that have ceased or lapsed in their entirety in ASX records before the announcement date described in Q1.5, even if the entity has advised ASX of a change to that class of +security in Part 2 of this form.